You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 247 No. 14, April 9, 1982 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL CARDIOLOGY
 This Article
 •References
 •Full text PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Should Prophylactic Antiarrhythmic Drug Therapy Be Used in Acute Myocardial Infarction?

Donald C. Harrison, MD; Larry E. Berte, MD

JAMA. 1982;247(14):2019-2021.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

FOLLOWING acute myocardial infarction, death generally results from two pathophysiological processes. In the period early after infarction, electrical processes such as primary ventricular fibrillation (fibrillation unassociated with heart failure or cardiogenic shock) accounts for the largest percentage of deaths. These deaths occur primarily in the first 24 hours after infarction and occur with a higher frequency during the first four hours from the onset of chest pain and with decreasing frequency through the next 20 hours. Later deaths from acute myocardial infarction may also be electrical. However, a mechanical process, defined as cardiogenic shock, congestive heart failure, or both owing to extensive necrosis of muscle and loss of the mechanical function of the heart, may account for many of these deaths. The final common pathway for many of these pump failures is also ventricular fibrillation (defined as secondary ventricular fibrillation).

Unlike primary ventricular fibrillation, a significant fraction of deaths in . . . [Full Text PDF of this Article]


Author Affiliations

From the Cardiology Division, Stanford University School of Medicine, Stanford, Calif.


Footnotes

This article is one of a series sponsored by the American Heart Association.

Reprint requests to the Cardiology Division, Stanford University School of Medicine, Stanford, CA 94305 (Dr Harrison).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.